Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditions.

NCT01260896 is registered in ClinicalTrials.gov with Teva Pharmaceuticals USA as lead sponsor.

NCT NCT01260896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01260896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditions.
Lead sponsor
Teva Pharmaceuticals USA
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2002
Completion date
October 31, 2002
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy